Addressable Market ExpansionAyon's integrated all-in-one body contouring capabilities, combined with growing patient demand for skin tightening linked to GLP-1 medication use, expand the addressable market and encourage adoption by high-volume surgeons.
Commercial TractionStrong U.S. demand for the Ayon system is driving clear commercial traction in the Surgical Aesthetics business, supporting revenue growth and increasing surgeon interest.
Profitability ImprovementApyx's move into adjusted EBITDA profitability reflects effective expense control and cash resources that increase visibility toward sustainable operating profitability.